Luminex to acquire flow cytometry portfolio from MilliporeSigma

Oct. 22, 2018

Luminex has signed a definitive agreement to acquire MilliporeSigma's flow cytometry portfolio for $75 million.

Luminex (Austin, TX) has signed a definitive agreement to acquire MilliporeSigma (Burlington, MA)'s flow cytometry portfolio for $75 million, consisting of approximately $69.9 million to be paid under a Stock and Asset Purchase Agreement and approximately $5.1 million in committed inventory purchases. The deal is expected to close by the end of 2018, and to contribute $40 million to $50 million in revenue to the company in 2019.

The acquisition expands Luminex's offering of flow-based detection systems, which is centered around its xMAP multiplexing technology that combines advanced fluidics, optics, and digital signal processing with its microsphere technology to deliver multiplexed assay capabilities.

MilliporeSigma's flow cytometry portfolio includes the Amnis imaging flow cytometry products for cell-based analysis, as well as the Guava high-performance systems based on microcapillary technologies.

For more information, please visit www.luminexcorp.com.

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)